|
1 Indications And Usage Gilotrif Is A Kinase Inhibitor Indicated For: First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (Nsclc) Whose Tumors Have Non-Resistant Epidermal Growth Factor Receptor (Egfr) Mutations As Detected By An Fda-Approved Test ( 1.1 ) Limitations Of Use : Safety And Efficacy Of Gilotrif Were Not Established In Patients Whose Tumors Have Resistant Egfr Mutations ( 1.1 ) Treatment Of Patients With Metastatic, Squamous Nsclc Progressing After Platinum-Based Chemotherapy ( 1.2 ) 1.1 Egfr Mutation-Positive, Metastatic Non-Small Cell Lung Cancer Gilotrif Is Indicated For The First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (Nsclc) Whose Tumors Have Non-Resistant Epidermal Growth Factor Receptor (Egfr) Mutations As Detected By An Fda-Approved Test [See Dosage And Administration (2.1) , Clinical Pharmacology (12.1) , Clinical Studies (14.1) ]. Limitations Of Use : The Safety And Efficacy Of Gilotrif Have Not Been Established In Patients Whose Tumors Have Resistant Egfr Mutations [See Clinical Studies (14.1) ]. 1.2 Previously Treated, Metastatic Squamous Nsclc Gilotrif Is Indicated For The Treatment Of Patients With Metastatic Squamous Nsclc Progressing After Platinum-Based Chemotherapy .
|